PubMed Health⌕ Search

Biomedical subjects

S Karanth

Publications and source records attributed to S Karanth.

At least 55 records · Page 3Linked to original sources
PubMed1993

The influence of interleukin-2 on the release of somatostatin and growth hormone-releasing hormone by mediobasal hypothalamus.

Interleukin-2 (IL-2), which plays a major role in the bidirectional intercellular communication between the neuroendocrine and immune systems, suppressed the release of GH from anterior pituitary halves at femtomolar concentrations. It is well established that the release of GH from the anterior pituitary is regulated by growth hormone releasing hormone (GRH) and growth hormone release-inhibiting hormone (somatostatin). Consequently, we studied the possible effect of IL-2 on the release of somatostatin and GRH from the mediobasal hypothalamus (MBH) in vitro. Single MBHs were incubated with fresh Krebs-Ringer bicarbonate (KRB) buffer alone or KRB containing different concentrations of IL-2 (10(-15)-10(-10) M) for 30 min. After collection of the media, the MBHs were incubated with KRB containing high potassium (high K+ = 56 mM) without IL-2 for a period of 30 min to study the effect of pretreatment with IL-2 on depolarization-induced somatostatin and GRH release. Experiments were also undertaken to study the effect of IL-2 in the presence of high K+ or IL-2 in the presence of DA (60 microM), a potent stimulator of somatostatin and GRH release. The minimal effective dose of IL-2 which significantly stimulated the release of somatostatin was 10(-14) M. Depolarization-induced release of somatostatin was reduced significantly by prior treatment with all the concentrations of IL-2 tested (10(-13)-10(-10) M).(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1993

Effect of phenobarbitone on pituitary gland of male albino mice.

The effects of phenobarbitone on gonadotrophs and lactotrophs of pituitary gland were studied in male albino mice which were administered phenobarbitone 50 mg/kg body weight intraperitoneally (ip) daily for 14 days. A group of control mice were administered saline ip. In the experimental group, there was significant reduction in the average cell population of FSH cells in the cephalomedian area (P < 0.001) and in the lateral lobe (P < 0.01). The average volume of both FSH and LH cells was also significantly reduced (P < 0.001). The changes in the gonadotrophs of the experimental group could be attributed to the negative feedback action of testosterone which is being secreted from hypertrophied Leydig cells of testis.

Animals↗
PubMed1992

Influence of dopamine on the altered release of prolactin, luteinizing hormone, and follicle-stimulating hormone induced by interleukin-2 in vitro.

Interleukin-2 (IL-2) alters the release of anterior pituitary hormones at femtomolar concentrations from hemipituitaries incubated in vitro. This cytokine significantly lowered luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and stimulated prolactin (PRL) release, thus demonstrating a reciprocal action of the lymphokine on lactotrophs and gonadotrophs. Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Hemipituitaries were incubated with varying concentrations of DA, a combination of IL-2 plus DA, or a combination of haloperidol (1 x 10(-5) M) with DA for 1 h, followed subsequently by incubation with medium containing only high potassium (K+) to study the effects on depolarization-induced hormone release. DA induced a dose-related, significant lowering of the basal PRL release with a minimal effective dose (MED) of less than 19 nM. The depolarization-induced PRL release was also inhibited, but the MED was 100-fold higher than the MED to inhibit basal PRL release. DA at much higher concentrations (30, 60, and 90 microM) significantly reduced pituitary PRL content. The addition of 0.187, 3.75, 15, or 60 microM DA to IL-2-induced PRL release. IL-2 (10(-15) M) produced a significant decrease in LH and FSH release. The combination of 3.75 or 15 microM DA plus IL-2 failed to alter the IL-2 suppressed LH release, whereas the addition of 0.187 microM DA to IL-2 blocked its suppressive influence, and 60 microM DA added to Il-2 produced an additive inhibitory effect. Thus, the interaction of IL-2 and DA is biphasic on LH release. The significant reduction of FSH release induced by IL-2 was blocked in the presence of 0.187, 3.75, 15, or 60 microM DA. DA alone at relatively high concentrations of 30, 60, and 90 microM suppressed basal LH and FSH release. The effects of DA on PRL, LH, and FSH at all doses tested were blocked by the DA receptor blocker, haloperidol which by itself at the concentration tested (1 x 10(-5) M) had no effect. Thus, the actions of DA at all concentrations tested appear to be mediated via DA receptors. In conclusion, DA was capable of blocking the stimulatory action of IL-2 on PRL release and its inhibitory action on FSH release by a DA receptor mediated action.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1992

Alterations in cerebrovascular reactivity after positive pressure ventilation.

Pressure ventilation of the newborn can adversely affect the cardiovascular system. Increasing airway pressure increases cerebral venous pressure, thus stressing brain vasculature. To test the hypothesis that cerebral venous distension caused by mechanical ventilation alters cerebral microvascular responses, we studied cerebrovascular responses before, during, and after positive pressure ventilation. Anesthetized newborn pigs were ventilated with a standard time-cycled, pressure-limited infant respirator. Pial arterioles were measured in response to hypercapnia, topical isoproterenol, and topical norepinephrine during control [mean airway pressure (Paw) = 0.9 +/- 0.05 kPa (4.8 +/- 0.3 cm H2O)] conditions, during 40-60 min of increased Paw [2.5 +/- 0.2 kPa (13.9 +/- 1.3 cm H2O)], and when the Paw was lowered again. Pial arteriolar dilation in response to hypercapnia was not changed by increasing Paw. Similarly, responses to isoproterenol and norepinephrine were unaltered during raised Paw. However, a significant decrease in responses to topical isoproterenol and norepinephrine was observed after increased Paw. These experiments show that specific prostanoid-independent cerebrovascular responses are altered subsequent to pressure ventilation, whereas prostanoid-dependent dilation to hypercapnia was not affected. These changes suggest that the newborn cerebral vasculature is affected by positive pressure ventilation, further raising the possibility that ventilation-induced alterations in microvascular responses could make the brain more vulnerable to added stresses after pressure ventilation.

Animals↗
PubMed1991

Anterior pituitary hormone control by interleukin 2.

Several monokines, proteins secreted by monocytes and macrophages, alter release of hormones from the anterior pituitary. We report here the ability of femtomolar concentrations of interleukin 2 (IL-2), a lymphokine released from T lymphocytes, to alter directly pituitary hormone release. The effects of concentrations of IL-2 ranging from 10(-17) to 10(-9) M on anterior pituitary hormone release were evaluated in vitro. Hemipituitaries were preincubated in 1 ml of Krebs-Ringer bicarbonate buffer (KRB) followed by incubation for 1 or 2 hr with KRB or KRB containing different concentrations of IL-2. This was followed by incubation for 30 min in 56 mM potassium medium to study the effect of pretreatment with IL-2 on subsequent depolarization-induced hormone release. Prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH), corticotropin (ACTH), growth hormone (GH), and thyrotropic hormone (TSH) released into the incubation medium were measured by radioimmunoassay. IL-2 stimulated the basal release of PRL at 1 or 2 hr but suppressed the subsequent depolarization-induced PRL release, perhaps because the readily releasable pool of PRL was exhausted. The minimal effective dose (MED) was 10(-15) M. Conversely, IL-2 significantly suppressed the basal release of LH and FSH at 1 or 2 hr, with a MED of 10(-16) M, thus demonstrating a reciprocal action of the cytokine on lactotrophs and gonadotrophs. The subsequent depolarization-induced release of LH and FSH was suppressed, indicative of a persistent inhibitory action of IL-2. IL-2 stimulated ACTH and TSH release at 1 hr and the MEDs were 10(-12) and 10(-15) M, respectively. Conversely, IL-2 significantly lowered the basal release of GH at 1 hr, with a MED of 10(-15) M. The release of GH was not altered at 2 hr. The high potassium-induced release of ACTH, TSH, and GH was not affected. The results demonstrate that IL-2 at picomolar concentrations affects the release of anterior pituitary hormones. This cytokine may serve as an important messenger from lymphocytes exerting a direct paracrine action on the pituitary by its release from lymphocytes in the gland or concentrations in the blood that reach the gland may be sufficient to activate it.

Adrenocorticotropic Hormone↗
PubMed1991

Diurnal variations and temporal coupling of bioactive and immunoactive luteinizing hormone, prolactin, testosterone and 17-beta-estradiol in adult men.

Diurnal variations and temporal coupling in the circulating levels of immunoactive and bioactive luteinizing hormone (LH) and prolactin (PRL), testosterone (T) and 17-beta-estradiol (E2) in plasma of 6 healthy men (mean age 33 years) were studied. Each hormonal profile was analyzed for circadian amplitude, acrophase and nadir. Acrophases for immunoactive LH and T were coincident and ranged between clock hours 1 and 5. Acrophase for bioactive LH ranged between 9 and 12 h and was coincident with nadir for T. Acrophase for E2 ranged between 15 and 18 h and was coincident with nadir for immunoactive LH (15-17 h). Acrophase for bioactive PRL and immunoactive PRL ranged between 20-23 and 23-4 h, respectively. The circadian amplitude for T showed a negative correlation coefficient with circadian amplitude of bioactive LH (alpha = -0.86) and positive correlation coefficient with circadian amplitude of immunoactive LH (alpha = 0.94). It is inferred that immunoactive LH may be a sensor of T concentration while bioactive LH may be actually involved in the feedback regulation of T secretion. It is suggested that PRL may have a key role in the regulation of LH secretion.

Adult↗
PubMed1989

Toxic shock-like syndrome associated with Bartholin's gland abscess: case report.

Herein is the first reported case of bartholinitis complicated by toxic shock-like syndrome. Streptococcal exotoxin is implicated in this case of nonmenstrual toxic shock-like syndrome, which is an increasingly recognized manifestation of streptococcal infection. Further surveillance, investigation, and reporting of streptococcal toxic shock-like syndrome are recommended.

Abscess↗
PubMed1987

Involvement of prostaglandin A1 in interrupting early pregnancy in Syrian golden hamsters.

The effects of a single administration of authentic prostaglandin A1 intravaginally in early pregnant hamsters were investigated. A single dose of 1 mcg/animal given on day 4 of pregnancy inhibited the appearance of embryonic swellings when observed on day 8 of pregnancy. A significant fall (p less than 0.01) in FSH with a rise (p less than 0.03) in prolactin concentration in the serum and no change in LH levels were observed. The pituitary content of prolactin showed a significant decrease (p less than 0.0006) with no change in FSH and LH contents. Progesterone concentration in the serum was markedly reduced (p less than 0.002), along with that of the ovaries (p less than 0.01). The decline in progesterone concentration coincided with the absence of corpora lutea and the embryos. However, no change in ovarian weights was observed. These results indicate the contragestive potential of prostaglandin A1. It appears to act as a luteolytic agent by disrupting the luteotropic complex (FSH:prolactin ratio).

Animals↗
PubMed1987

Age-related release of prolactin by the pituitary and the pituitary-hypothalamic complex in vitro: an attempt to describe the development of the hypothalamic prolactin-inhibiting and -releasing activities in male rats.

We have recently demonstrated that the pituitary hypothalamic complex (PHC) is a good model for studying interactions between the hypothalamus and pituitary in vitro. The amount of prolactin secreted by the PHC is an index of prolactin secreted by the pituitary in the presence of hypothalamic control, while the amount released by the whole pituitary alone is an index of prolactin secreted in the absence of hypothalamic control. The amount of prolactin secreted by the PHC has been regarded as an index of hypothalamic prolactin-releasing activity (HPRA), while the difference in the amounts of prolactin secreted by the whole pituitary and the PHC is the hypothalamic prolactin-inhibiting activity (HPIA). Attempts were made to correlate HPRA and HPIA to the development of serum concentrations of prolactin from days 7 to 77 in male rats. The HPRA increased steadily from days 7 to 56, decreased significantly on day 63 and thereafter remained unchanged until day 77. The HPIA was low on days 7 and 14 and increased steadily up to day 49, with no further significant variations. The developmental patterns of HPRA and HPIA were comparable up to day 49. Serum concentrations of prolactin increased significantly until day 28 and remained fairly constant until day 49. The weight of the pituitary gland increased from 1.0 +/- 0.03 mg (mean +/- S.E.M.) on day 7 to 7.76 +/- 0.32 mg on day 63 and remained unchanged thereafter. The weight of the hypothalamic islet was 31.5 +/- 2.88 mg on day 7, 34.83 +/- 1.45 mg on day 14 and 50.4 +/- 4.01 mg on day 21. After day 21 the weights of the hypothalamic islets were not significantly altered, except on day 49. It was concluded that serum concentrations of prolactin are regulated by interaction or competition between HPRA and HPIA at the level of the pituitary.

Aging↗
PubMed1986

The choice of a model for studying the hypothalamus-pituitary interactions in vitro.

Comparative studies on the release of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prolactin (Prl) by the whole pituitary, pituitary plus hypothalamus and pituitary-hypothalamus complex (PHC) were undertaken to choose an appropriate model for studying the hypothalamus-pituitary interactions in vitro and to relate the importance of the intact neural connections between pituitary and hypothalamus on hypothalamus-pituitary interactions. Also the effect of including dopamine (DA) at 1 X 10(-7) mol/1 in these different in vitro systems on the release of LH, FSH and Prl was investigated. The pituitary released increasing amounts of LH and FSH at 2, 4 and 6 h but the amount of Prl released remained unchanged. The rates of release of LH, FSH and Prl by the pituitary were different and were characteristic of each hormone. Co-incubation of pituitary with hypothalamus stimulated the release of LH and FSH but inhibited the release of Prl. Pituitary-hypothalamus complex behaved almost identical to behaved almost identical to pituitary plus hypothalamus system. Inclusion of 1 X 10(-7) M DA in the incubation medium stimulated the release of LH (80%) but inhibited the release of Prl (71%) by PHC. FSH was unaffected. DA had no significant effect on the release of LH, FSH and Prl by pituitary and pituitary plus hypothalamus systems. It is suggested that PHC is the system of choice for studying hypothalamus-pituitary interactions in vitro.

Animals↗
PubMed1986

Ontogeny of serum and pituitary gonadotrophins in male rats treated with low doses of 5 alpha-dihydrotestosterone.

The effect of s.c. daily injections of 10 or 1000 ng 5 alpha-dihydrotestosterone (DHT)100 g body weight from birth to day 21, or from days 26 to 117 of age, on the changes in concentration of serum and pituitary gonadotrophins was investigated in male rats. Treatment with 10 ng DHT from days 1 to 21 depressed serum FSH, but not LH, at day 7, while 1000 ng DHT depressed both serum LH and FSH. Treatment with both doses of DHT reduced pituitary levels of LH and FSH at day 7, with FSH being more depressed than LH. Treatment with 10 ng DHT from days 26 to 117 increased serum FSH from days 82 to 117, while 1000 ng DHT did not have this effect. Treatment with 1000 ng, but not 10 ng, DHT between days 26 and 117 reduced pituitary levels of LH and FSH at day 40. Rats treated with the two doses of DHT from days 26 to 117 showed a difference in the responsiveness of the pituitary to LH-releasing hormone (LHRH). Treatment with 10 ng DHT enhanced LHRH-induced release of LH without affecting FSH release, while 1000 ng DHT depressed LHRH-induced release of FSH but not of LH. These findings support the view that DHT may play a modulatory role in the ontogeny of serum gonadotrophins and the responsiveness of the pituitary to LHRH during the onset of puberty in the male rat.

Animals↗
PubMed1985

Effect of castration and steroid treatment on the release of gonadotropins by the rat pituitary-hypothalamus complex in vitro.

Comparative in vitro studies on the release of LH and FSH by pituitary-hypothalamus complex (PHC) with intact portal plexus and whole pituitary (PI) from adult male rats showed that PHC released LH at a greater rate and in larger amounts than PI. PHC and PI released FSH in comparable amounts and rates. Attempts were made to correlate serum gonadotropin levels to that released by PHC and PI at 1, 3, 7, 14, 21 and 46 days of post-castration (PC). Sham operated animals served as controls. Castration increased serum LH and FSH levels but in different profiles. CPHC and CPI (PHC and PI from castrated rats) released less LH than NPHC and NPI (PHC and PI from sham operated controls) till day 14 PC after which CPHC and CPI released more LH than NPHC and NPI respectively. Castration abolished the intrinsic capacity of PHC to secrete more LH than PI. CPHC and CPI secreted significantly less FSH than NPHC and NPI at 1, 3 and 7 days PC. At days 14 and 21 of post-castration PCNCP or CPI and NPHC or NPI released similar amounts of FSH. Administration of 5 alpha-dihydrotestosterone (DHT, 1 mg/rat/day) or estradiol valerate (EV, 1 microgram/rat/day) immediately following castration prevented the rise in serum LH and FSH but increased the amounts of LH and FSH released by CPHC and CPI. The treatment caused a marked stimulation of FSH released by CPI.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1984

Studies on the effects of low doses of 5 alpha-dihydrotestosterone (DHT) on the basal levels of serum gonadotropins and the sensitivity of the pituitary to luteinizing hormone releasing hormone (LHRH) in adult male rats.

Investigations were undertaken to study the effect of administering s.c. 10, 25, 50, 100, 500 and 1000 ng DHT/rat/day to normal adult male rats, for six weeks, on the basal levels of serum gonadotropin and the sensitivity of the pituitary to LHRH. The control group received olive oil. Animals were weighed and bled via cardiac puncture before the beginning of the treatment and weekly thereafter. After the last bleeding rats were injected intracardially 200 ng LHRH/rat and killed 15 min later. Blood, pituitary and testes were collected. Data were analyzed with respect to the control group and with respect to day zero of the treatment. DHT failed to produce a persistent effect on the serum gonadotropin. 10 and 500 ng DHT suppressed FSH levels significantly on days 21 and 7, respectively. 25, 50, 100 and 1000 ng DHT stimulated the release of FSH on day 42. 10 ng DHT reduced the levels of LH on day 14 of the treatment. 10, 25 and 50 ng DHT increased the sensitivity of the pituitary to release more LH in response to LHRH while 100, 500, 1000 ng DHT inhibited LHRH induced release of FSH. DHT at all doses tested failed to affect intrapituitary levels of LH and FSH. 10, 500 and 1000 ng DHT reduced the weights of the pituitaries as compared to the control group. The data demonstrate effects of DHT which are transient on the basal release of gonadotropins but are more persistent and differential on the sensitivity of the pituitary to LHRH.

Animals↗
PubMed1982

An assessment of inhibin-like activity secreted by Sertoli cells in culture using castrated adult male rats.

Sertoli cells isolated from testes of 16-18 days old male rats were maintained in culture. Incubation media from these culture were pooled on day 7 and tested for its inhibin-like activity either with (SCCM) or after charcoal treatment (CSCCM) in castrated adult male rats. The assay was based on the tacit assumption that SCCM or CSCCM would specifically lower circulating blood serum levels of FSH. Subcutaneous (sc)injections of CSCCM at a dose level of 1 mg protein per rat, per day, x 3 days caused a specific suppression of FSH levels, while lower dosages of CSCCM (Protein content of 300 micrograms or 600 micrograms/rat/day, x 3 days) were without any affect on basal levels of FSH and LH. SCCM was ineffective at all dose levels tested. Intracardiac injections of varying doses of LHRH (25 to 400 ng/rat) to CSCCM pre-treated rats (200 micrograms/rat/day, x 3 days) failed to increase the levels of LH and FSH. These results support the presence of inhibin like activity in SCCM by a bioassay procedure alternate to in vitro pituitary cell culture system used by other investigators.

Animals↗
PubMedDate not supplied

Control of gonadotropin secretion by follicle-stimulating hormone-releasing factor, luteinizing hormone-releasing hormone, and leptin.

Fractionation of hypothalamic extracts on a Sephadex G-25 column separates follicle-stimulating hormone-releasing factor (FSHRF) from luteinizing hormone-releasing hormone (LHRH). The FSH-releasing peak contained immunoreactive lamprey gonadotropin-releasing hormone (lGnRH) by radioimmunoassay, and its activity was inactivated by an antiserum specific to lGnRH. The identity of lGnRH-III with FSHRF is supported by studies with over 40 GnRH analogs that revealed that this is the sole analog with preferential FSH-releasing activity. Selective activity appears to require amino acids 5-8 of lGnRH-III. Chicken GnRH-II has slight selective FSH-releasing activity. Using a specific lGnRH-III antiserum, a population of lGnRH-III neurons was visualized in the dorsal and ventral preoptic area with axons projecting to the median eminence in areas shown previously to control FSH secretion based on lesion and stimulation studies. Some lGnRH-III neurons contained only this peptide, others also contained LHRH, and still others contained only LHRH. The differential pulsatile release of FSH and LH and their differential secretion at different times of the estrous cycle may be caused by differential secretion of FSHRF and LHRH. Both FSH and LHRH act by nitric oxide (NO) that generates cyclic guanosine monophosphate. lGnRH-III has very low affinity to the LHRH receptor. Biotinylated lGnRH-III (10(-9) M) labels 80% of FSH gonadotropes and is not displaced by LHRH, providing evidence for the existence of an FSHRF receptor. Leptin has equal potency as LHRH to release gonadotropins by NO. lGnRH-III specifically releases FSH, not only in rats but also in cows.

Animals↗